Company Announcement - Glucotrack Inc announced the appointment of Peter C Wulff as Chief Financial Officer effective immediately [1] - Peter C Wulff brings over 35 years of financial management experience in the life sciences sector with a strong track record in capital raising and strategic transactions [2] - The new CFO expressed enthusiasm about commercializing Glucotrack's technology and supporting the company's long-term strategic vision [3] Leadership Commentary - Glucotrack's President and CEO highlighted Wulff's exceptional track record in delivering results and creating value [4] - The CEO emphasized Wulff's extensive experience in capital markets and strategic planning as valuable assets for advancing the company's continuous blood glucose monitor through clinical development and future commercialization [4] Company Overview - Glucotrack Inc is a medical technology company focused on developing novel technologies for people with diabetes [5] - The company is developing a long-term implantable continuous blood glucose monitoring system [5] - Glucotrack's CBGM features a 3-year sensor longevity, no on-body wearable component, and minimal calibration requirements [6] Product Information - Glucotrack's Continuous Blood Glucose Monitor (CBGM) is a long-term implantable system designed for continuous glucose measurement [6] - The CBGM system offers significant advantages including extended sensor life and reduced user burden compared to traditional monitoring methods [6]
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer